Surosh Nazeer, MD
Endocrinology, Diabetes & Metabolism · Greenbelt, MDNPI 1295197390
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 364 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations.
Across 364 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Cequr Corporation$881
- Corcept Therapeutics$718
- Xeris Pharmaceuticals, Inc.$429
- Sanofi-aventis U.S. LLC$420
- plus $3K from 33 others
What the payments were for
- Food & beverage$8,56599%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $1,357 |
| Lilly USA, LLC | 63 | $1,332 |
| Cequr Corporation | 4 | $881 |
| Corcept Therapeutics | 27 | $718 |
| Xeris Pharmaceuticals, Inc. | 22 | $429 |
| Sanofi-aventis U.S. LLC | 17 | $420 |
| Amneal Pharmaceuticals LLC | 19 | $409 |
| Radius Health, Inc. | 19 | $373 |
| Insulet Corporation | 11 | $258 |
| AbbVie | 9 | $205 |
| Bayer | 9 | $204 |
| Amgen(2 entities) | 11 | $200 |
| Antares Pharma, Inc. | 7 | $164 |
| Recordati_rare_diseases_inc. | 8 | $162 |
| AstraZeneca(2 entities) | 6 | $143 |
| Boehringer Ingelheim | 6 | $124 |
| Astellas Pharma US Inc | 6 | $122 |
| Abbott | 6 | $120 |
| Tandem Diabetes Care, Inc. | 5 | $109 |
| Amphastar Pharmaceuticals, Inc. | 5 | $98 |
| Madrigal Pharmaceuticals | 5 | $93 |
| Medtronic | 3 | $89 |
| Ascensia Diabetes Care US Inc. | 4 | $80 |
| Tolmar, Inc. | 4 | $67 |
| Kyowa Kirin, Inc. | 3 | $62 |
| Acella Pharmaceuticals, LLC | 3 | $50 |
| Dexcom, Inc. | 2 | $48 |
| Halozyme Inc | 2 | $42 |
| Amryt Pharma Holdings Ltd | 2 | $35 |
| Sandoz | 1 | $32 |
| BD | 1 | $31 |
| Boston Scientific | 1 | $28 |
| BETA Bionics, Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $25 |
| EUSA Pharma (US) LLC | 1 | $21 |
| Nevro Corp. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$786
How this compares
$8,634 in reported general payments places this provider in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 167 | $212,087 |
| JardianceEmpagliflozin | 116 | $125,894 |
| OzempicSemaglutide | 64 | $112,794 |
| Tresiba Flextouch U-200Insulin Degludec | 102 | $106,444 |
| RybelsusSemaglutide | 43 | $83,508 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 30 | $66,703 |
| TrulicityDulaglutide | 37 | $50,837 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $47,885 |
| JanuviaSitagliptin Phosphate | 22 | $26,339 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $24,600 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $21,930 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $19,873 |
| Humalog Kwikpen U-100Insulin Lispro | 48 | $11,484 |
| Cinacalcet Hcl | 23 | $9,531 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 15 | $7,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,332 | $262,924204 claims |
| Novo NordiskOzempic, Rybelsus | $1,357 | $196,302107 claims |
| Boehringer IngelheimJardiance | $124 | $125,894116 claims |
| Cequr CorporationCequr Simplicity | $881 | $7,21715 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $409 | $1,731152 claims |
| AbbVieSynthroid | $205 | $48012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Greenbelt
- Irfan KhanGreenbelt$11K
- Sabreen AhmedGreenbelt$10K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.